Studies of Pregabalin/Lyrica Show a Risk of Dementia
Pregabalin is a drug also known by the brand name Lyrica. It’s used to treat epilepsy and nerve pain. It is sometimes used off label to treat chronic back pain, anxiety, or insomnia. Several studies show that pregabalin use is linked to cognitive decline. A study of 2 million people in Taiwan also shows that there is a link to increased risk of dementia, one of the most prevalent neurodegenerative disorders worldwide, which causes progressive impairments in executive function, memory, learning, and ability to perform daily activities. The research data for the study, which also included gabapentin, was collected from January 2000–December 2017. Around 206,802 patients were involved with the study. Around 34,467 of those taking pregabalin or gabapentin and 172,335 non-exposed people were analyzed. The risk of dementia increased with higher cumulative daily doses during a follow-up period. Moreover, the risk of dementia associated with pregabalin exposure was higher in patients under the age of 50 than older patients. If a loved one is experiencing dementia or cognitive decline and you believe it’s the result of exposure to pregabalin, you should consult the seasoned Chicago-based product liability attorneys of Moll Law Group to determine whether you have a viable claim.
Contact Moll Law Group About Your Pregabalin or Lyrica Claim
Originally, pregabalin was approved for neuropathic pain and partial seizures. However, it is increasingly used off-label, and often it’s prescribed for young people. Numerous factors can go into the risk of developing dementia, and around 50 million people live with dementia around the world. The prevalence of dementia is rising, and so the increase in pregabalin prescriptions and the associated cognitive adverse effects is of particular concern.
Illinois Injury and Mass Tort Lawyer Blog





Gabapentin is a prescription medication, gamma aminobutyric acid (GABA) analogue, that reduces the excitability of neurons. It is used to control and prevent partial seizures, to relieve neuralgia, and to treat restless legs syndrome. It’s also used off label to address anxiety disorders, migraines, insomnia, drug and alcohol withdrawal symptoms, and for non-approved pain problems like nerve pain from sciatica. The brand names of gabapentin are Neurontin, Horizant, and Gralise. Some states have classified gabapentin as a Schedule V controlled substance due to the number of deaths from overdose, but prescriptions are climbing anyway.
On August 3, 2026, plaintiffs filed
In June, the Consumer Product Safety Commission (CPSC) and Galanz Americas Limited announced a recall of the latter’s
In August, Louisville, Featherlite, Lite & Century Attic Stairway Ladders with gas struts were
On August 6, 2026, OKK Trading
On June 11, 2026,
On June 4, TOMY recalled its 8 oz.
On June 11, 2026, Joyin, the manufacturer of Sloosh dive sticks
Recently, a number of lawsuits against AI companies have sought to use product liability theory and strategy to hold them accountable for injuries to consumers, especially minors. Some pundits have called this a Big Tobacco moment— using product liability law in this context is novel; but these theories were also successfully used to go after big tobacco companies in the 1990s and to achieve multibillion dollar settlements and changes to cigarette marketing. One of the most prominent pieces of current AI litigation is Florida’s